A share price of Summit Therapeutics Inc [SMMT] is currently trading at $20.79, up 8.34%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The SMMT shares have gain 16.93% over the last week, with a monthly amount glided 6.23%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Summit Therapeutics Inc [NASDAQ: SMMT] stock has seen the most recent analyst activity on March 12, 2025, when Evercore ISI initiated its Outperform rating and assigned the stock a price target of $30. Previously, Goldman started tracking the stock with Buy rating on February 28, 2025, and set its price target to $42. On January 08, 2025, Truist initiated with a Buy rating and assigned a price target of $35 on the stock. Wells Fargo started tracking the stock assigning a Overweight rating and suggested a price target of $30 on December 11, 2024. Jefferies initiated its recommendation with a Buy and recommended $31 as its price target on December 06, 2024. JMP Securities started tracking with a Mkt Outperform rating for this stock on November 04, 2024, and assigned it a price target of $32. In a note dated September 27, 2024, Citigroup downgraded an Neutral rating on this stock and boosted its target price from $19 to $23.
Summit Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $2.10 and $33.89. Currently, Wall Street analysts expect the stock to reach $38 within the next 12 months. Summit Therapeutics Inc [NASDAQ: SMMT] shares were valued at $20.79 at the most recent close of the market. An investor can expect a potential return of 82.78% based on the average SMMT price forecast.
Analyzing the SMMT fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.51, Equity is -0.83 and Total Capital is -0.54. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 19.56 points at the first support level, and at 18.33 for the second support level. However, for the 1st resistance point, the stock is sitting at 21.66, and for the 2nd resistance point, it is at 22.53.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Summit Therapeutics Inc [NASDAQ:SMMT] is 10.15. As well, the Quick Ratio is 10.15, while the Cash Ratio is 2.51.
Transactions by insiders
Recent insider trading involved Zanganeh Mahkam, Chief Executive Officer, that happened on Mar 27 ’24 when 54321.0 shares were purchased. Chief Executive Officer, Zanganeh Mahkam completed a deal on Mar 26 ’24 to buy 30000.0 shares. Meanwhile, Chief Executive Officer Zanganeh Mahkam bought 26000.0 shares on Mar 27 ’24.
